- Details
- At the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual conference, Justin Ferdindandus presents the results of a study which evaluated whether baseline imaging can provide prognostic information in patients treated with lutetium PSMA regarding overall survival and progression-free survival. The post-hoc analysis revealed that a favorable response by the means of a 50% PSA d...
|
- Details
- Lorelei Mucci and Elizabeth Platz join Charles Ryan in a discussion on the impact of vitamin D and statins on prostate cancer outcomes. There is no direct evidence linking vitamin D and the risk of prostate cancer, however, vitamin D is believed to be important for overall good health. There is an inverse relationship between cholesterol and risk for the development of prostate cancer and statin u...
|
- Details
- Elena Castro, MD joins Alicia Morgans, MD, MPH at the 2019 Prostate Cancer Foundation Retreat (PCF 2019) to discuss PROREPAIR-B. This was an academic prospective observational study evaluating the prevalence and impact of germline mutations in BRCA1, BRCA2, ATM and PALB2 on metastatic castration-resistance prostate cancer (mCRPC) outcomes. Biographies: Elena Castro, MD, Prostate Cancer and Genitou...
|
- Details
- Rebecca Roe speaks to an interdisciplinary approach to implementation of Blue Light Cystoscopy (BLC™) in her community hospital center, giving a Clinical Education Program Coordinator's perspective. Her team engaged in the five management practices looking at ongoing communication and clinical training and measured things along the way, seeking feedback from every discipline that was utilized, whe...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019), Alicia Morgans is joined by the four women leaders and organizers of the Prostate Cancer Foundation's Women in Science Forum 2019. Himisha Beltran, Lorelei Mucci, Karen Knudsen, and Amina Zoubeidi each share their insights and motivations for leading the forum. Each of these professionals is moving the field forward...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019), Stacey Kenfield joins Charles Ryan to speak about her work on lifestyle, exercise, nutrition and its impact on prostate cancer. She talks about the Prostate 8 program which resulted from looking at men with prostate cancer and studying different dietary and lifestyle factors that might be associated with prostate can...
|
- Details
- Kenneth Pienta joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019) to discuss the biology of prostate cancer, and to share a clinician's perspective of thinking about the biology of this disease. This is a look at the current year and some of the significant findings that have changed the way we look at treating prostate cancer. The STAMPEDE data sho...
|
- Details
- In this conversation, Ronac Mamtani and Ravi Parikh join Alicia Morgans to discuss their recent work on bladder cancer outcomes and effectiveness research. They discuss immune checkpoint therapy versus carboplatin chemotherapy in patients with metastatic urothelial cancer (mUC). They also discuss the "Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cance...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Joaquin Mateo, Principal Investigator, and Translational Scientist at the Vall d'Hebron hospital in Barcelona joined Charles Ryan to discuss how PARP inhibitors are being integrated into the standard of care for prostate cancer, pivotal studies that are reporting and ongoing with PARP inhibitors, and important aspect of t...
|
- Details
- Scott Tagawa joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses advances in bladder and prostate cancer. He highlights his recent work on antibody-drug conjugates (ADCs) specifically, sacituzumab govitecan in metastatic urothelial cancer and the and the initial results from TROPHY-U-01. Although immune checkpoint inhibitors now provide an...
|
